Develops drugs for dermatological conditions, including actinic keratosis.
Jun 2026Revenue $46.2M/yrExpenses $52.7M/yr
No trendCash runway ≈ 7 months from Jun 2026
Figures by year
When will Biofrontera be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $46.2M and expenses $52.7M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $41.7M | $53.1M | −$11.3M |
| Dec 2024 | $37.3M | $54.5M | −$17.2M |
| Dec 2023 | $34.1M | $56.7M | −$22.7M |
| Dec 2022 | $28.7M | $47.3M | −$18.6M |
| Dec 2021 | $24.1M | $49.3M | −$25.2M |
| Dec 2020 | $18.8M | $28.5M | −$9.61M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.